JP2018503668A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503668A5
JP2018503668A5 JP2017540549A JP2017540549A JP2018503668A5 JP 2018503668 A5 JP2018503668 A5 JP 2018503668A5 JP 2017540549 A JP2017540549 A JP 2017540549A JP 2017540549 A JP2017540549 A JP 2017540549A JP 2018503668 A5 JP2018503668 A5 JP 2018503668A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
phe
composition according
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540549A
Other languages
English (en)
Japanese (ja)
Other versions
JP6613312B2 (ja
JP2018503668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/055305 external-priority patent/WO2016061087A1/en
Publication of JP2018503668A publication Critical patent/JP2018503668A/ja
Publication of JP2018503668A5 publication Critical patent/JP2018503668A5/ja
Application granted granted Critical
Publication of JP6613312B2 publication Critical patent/JP6613312B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540549A 2014-10-14 2015-10-13 膵臓癌を処置するためのペプチドをベースとする方法 Expired - Fee Related JP6613312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063909P 2014-10-14 2014-10-14
US62/063,909 2014-10-14
PCT/US2015/055305 WO2016061087A1 (en) 2014-10-14 2015-10-13 Peptide-based methods for treating pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2018503668A JP2018503668A (ja) 2018-02-08
JP2018503668A5 true JP2018503668A5 (enExample) 2018-11-22
JP6613312B2 JP6613312B2 (ja) 2019-11-27

Family

ID=54365375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017540549A Expired - Fee Related JP6613312B2 (ja) 2014-10-14 2015-10-13 膵臓癌を処置するためのペプチドをベースとする方法
JP2017540551A Active JP7023709B2 (ja) 2014-10-14 2015-10-13 抗炎症特性を有するペプチド
JP2020118752A Pending JP2020180149A (ja) 2014-10-14 2020-07-09 抗炎症性組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017540551A Active JP7023709B2 (ja) 2014-10-14 2015-10-13 抗炎症特性を有するペプチド
JP2020118752A Pending JP2020180149A (ja) 2014-10-14 2020-07-09 抗炎症性組成物

Country Status (10)

Country Link
US (5) US10016480B2 (enExample)
EP (2) EP3206703B1 (enExample)
JP (3) JP6613312B2 (enExample)
KR (3) KR20230004907A (enExample)
CN (2) CN107106638A (enExample)
AU (2) AU2015333678B2 (enExample)
BR (1) BR112017007543A2 (enExample)
CA (2) CA2964361A1 (enExample)
WO (2) WO2016061087A1 (enExample)
ZA (1) ZA201702537B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3653212B1 (en) 2012-12-20 2023-04-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
WO2017149012A1 (en) * 2016-03-02 2017-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides and uses thereof for reducing cd95-mediated cell motility
SG11201807770RA (en) * 2016-03-24 2018-10-30 Nantcell Inc Sequence arrangements and sequences for neoepitope presentation
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
JP7537074B2 (ja) 2016-05-10 2024-08-21 ソルボンヌ ウニベルシテ Ｃｄ４７を活性化する作用物質およびその炎症治療における使用
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TW201803598A (zh) 2016-06-30 2018-02-01 南特細胞公司 Ｎａｎｔ癌症疫苗
CN106432014B (zh) * 2016-09-05 2019-08-16 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
WO2018086562A1 (en) * 2016-11-09 2018-05-17 Shen Tang Long Method for treatment or prevention of cancer
US20190358263A1 (en) * 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
JP7051898B2 (ja) 2017-04-24 2022-04-11 ナントセル，インコーポレイテッド 標的型ネオエピトープベクター及びそのための方法
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
ES3041991T3 (en) 2017-05-25 2025-11-17 Leidos Inc Pd-1 and ctla-4 dual inhibitor peptides
EP3687559B1 (en) 2017-09-29 2025-11-12 Sanford Burnham Prebys Medical Discovery Institute Compositions that target tumor-associated macrophages and methods of use therefor
CN109745324B (zh) * 2017-11-06 2026-02-06 中国科学院上海营养与健康研究所 非经典NF-kB通路的小分子抑制剂及其应用
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
AU2018410849B2 (en) * 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
US12383537B2 (en) * 2018-06-20 2025-08-12 Universidade De Coimbra (3S)-and (3R)-6,7-bis(hydroxymethyl)-1H,3H-pyrrolo[1,2-c]thiazoles as P53 activators
EP3836955A4 (en) * 2018-08-15 2022-05-18 The Regents of the University of California IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY
CN112840211B (zh) * 2018-08-27 2024-11-12 南特生物公司 Rp182组合物及方法
US20220143130A1 (en) * 2018-08-29 2022-05-12 Riptide Bioscience, Inc. Peptides Having Immunomodulatory Properties
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
WO2020046297A2 (en) * 2018-08-29 2020-03-05 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
US20220053773A1 (en) * 2018-10-01 2022-02-24 Innate Immunity LLC Compositions and methods for the treatment of pathogenic infections in plants
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
WO2020176478A1 (en) 2019-02-25 2020-09-03 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
CA3134420A1 (en) * 2019-04-12 2020-10-15 Riptide Bioscience, Inc. Methods for modulating macrophage activity
JP7606471B2 (ja) 2019-05-22 2024-12-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
US20220125866A1 (en) * 2019-06-28 2022-04-28 Nantcell, Inc Pharmaceutical compositions to enhance phagocytosis without inflammation
CN115768757B (zh) 2019-12-19 2025-07-11 美利坚合众国,由健康及人类服务部部长代表 Cd206调节剂及其用途和制备方法
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
EP4100428A4 (en) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
AU2021246017A1 (en) * 2020-03-31 2022-11-10 Innate Immunity LLC Recombinant peptide to treat fire blight
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
WO2022081426A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
EP4365187A4 (en) * 2021-06-28 2025-11-19 Univ Korea Res & Bus Found Peptide with anticancer activity and its use
CN115607674B (zh) * 2021-07-15 2023-09-19 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
WO2023080578A1 (ko) * 2021-11-05 2023-05-11 주식회사 레메디 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도
WO2023097111A2 (en) * 2021-11-29 2023-06-01 Riptide Bioscience, Inc. Methods and compositions for treating calcinosis associated conditions
WO2023111695A1 (en) * 2021-12-16 2023-06-22 Ramakrishna Reddy Isanaka A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
KR102920640B1 (ko) 2022-03-11 2026-01-29 국립순천대학교산학협력단 항진균 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항진균용 조성물
WO2024102993A1 (en) * 2022-11-10 2024-05-16 Research Foundation Of The City University Of New York Cationically-enframed high density aromatic peptides
CN115838395A (zh) * 2022-11-15 2023-03-24 西北农林科技大学 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用
CN116768970A (zh) * 2023-05-19 2023-09-19 重庆师范大学 抗氧化多肽、制备方法及其应用
CN118530299B (zh) * 2023-08-25 2025-02-07 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
WO2025093952A1 (en) * 2023-10-30 2025-05-08 Ramakrishna Reddy Isanaka Peptide with anti-inflammatory and anti-microbial activity
WO2025255373A2 (en) * 2024-06-05 2025-12-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fatty acid and cyclized derivatives of the immunomodulatory peptide rp-182 with improved anti-tumor activity, compositions, and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE127838T1 (de) 1987-07-06 1995-09-15 Univ Louisiana State Inhibierung von eukaryotischen pathogenen und neoplasmen mit lytischen peptiden.
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
EP1004595B1 (en) 1989-04-10 2003-06-18 Helix BioMedix, Inc. Lytic and proliferative peptides and their use as pharmaceutic and phytopharmaceutic agents
AU2514592A (en) * 1991-08-21 1993-03-16 Board Of Regents, The University Of Texas System Methods and compositions for modulating g protein action
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5955573A (en) 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
AU1086595A (en) 1993-11-08 1995-05-29 Demeter Biotechnologies, Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
IL114697A0 (en) * 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
AU4602897A (en) 1996-10-04 1998-04-24 Demegen, Inc. Method for treatment of immunodeficiency virus infection
DE19711831C2 (de) 1997-03-21 2000-07-13 Daimler Chrysler Ag Schmelzinfiltrierte faserverstärkte Verbundkeramik und Verfahren zur Herstellung einer solchen
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
AU6587998A (en) * 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
JP2003506411A (ja) * 1999-08-09 2003-02-18 トリペップ アクチ ボラゲット タンパク質重合阻害剤および使用方法
WO2002079408A2 (en) 2001-03-28 2002-10-10 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7091185B2 (en) * 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
GB0326393D0 (en) 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
US7288622B1 (en) * 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101485885B (zh) * 2009-01-09 2012-06-27 中国科学院广州生物医药与健康研究院 蛋白磷酸酯酶PPM1E作为疾病的治疗靶标及其应用和siRNA
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
US20120270770A1 (en) 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
US9487560B2 (en) 2013-05-02 2016-11-08 ISSAR Pharmaceuticals Ltd Angiogenic active lytic peptides
CA2964361A1 (en) * 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Peptide-based methods for treating pancreatic cancer
US9737584B2 (en) * 2015-08-11 2017-08-22 Issar Pharmaceuticals Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring

Similar Documents

Publication Publication Date Title
JP2018503668A5 (enExample)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
JP2016527286A5 (enExample)
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2018521135A5 (enExample)
JP2017523781A5 (enExample)
JP2018523703A5 (enExample)
TW201613958A (en) MIC-1 fusion proteins and uses thereof
JP2016509011A5 (enExample)
JP2018510132A5 (enExample)
JP2016502515A5 (enExample)
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
HRP20192174T1 (hr) Kombinirani farmaceutski pripravak
JP2015510393A5 (enExample)
JP2017503014A5 (enExample)
JP2013515745A5 (enExample)
JP2017521486A5 (enExample)
JP2014526881A5 (enExample)
JP2016506413A5 (enExample)
MX2020006822A (es) Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa.
JP2019533722A5 (enExample)
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)